Cyclophosphamide

T-Cell Non-Hodgkin Lymphoma

GC Cell CorporationSmall moleculePhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 89/ 100

Competitive context

83 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine GC Cell Corporation	Phase 2	BBB
Brentuximab Vedotin Yale University	Phase 4	BBB
Rituximab Memorial Sloan Kettering Cancer Center	Phase 2	BB
LENALIDOMIDE Samsung Medical Center	Phase 2	BB
TACROLIMUS M.D. Anderson Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

79 / 100

mycosis fungoidesActive

BBB

Indicative · Phase 4

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative · Phase 3

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.